iDepartment of Medicine, Division of Respirology, University Health Network, Toronto, ON, Canada jInstitute of Health Policy, Management, and Evaluation at the University of Toronto, Toronto, ON, ...

Objectives COVID-19 causes lung parenchymal and endothelial damage that lead to hypoxic acute respiratory failure (hARF). The influence of hARF severity on patients’ outcomes is still poorly ...

In a recent study investigating the effects of prostaglandin E1 (PGE1) on reducing inspired oxygen concentration during one-lung ventilation (OLV), several key findings and outcomes were identified.

Acute respiratory distress syndrome is a significant complication in critical care patients. COVID-19 (C19)-associated severe respiratory failure is related to it, and d-dimer rise predicts a worse ...

The following is a summary of “Clinical Performance of Spo 2 /Fio 2 and Pao 2 /Fio 2 Ratio in Mechanically Ventilated Acute Respiratory Distress Syndrome Patients: A Retrospective Study,” published in ...

Lungpacer Medical, the award-winning medical device company founded by BPK professor Andy Hoffer in 2009 and spun out from the SFU Neurokinesiology Lab in 2014, achieved a key milestone on December 5, ...

Lung ultrasound is a developing and beneficial method for identifying compromised alveolar air and the presence of interstitial and alveolar fluid. It assesses lung aeration beyond the pleura and can ...

The following is a summary of “Prognostic value of PaO2/FiO2 ratio in predicting clinical outcomes in COVID-19 patients,” published in the June 2024 issue of Critical Care by Canto-Costal et al.

The models use maximal deflection of esophageal pressure to quantify HFOT-related breathing effort (ΔPes) and the risk for strong breathing effort (ΔPes >10 cmH2O). Two models have been developed to ...